fashion -WSS

fashion

author：hotspot 2025-08-24 10:15:00 - browse：16973

This image provided by Eisai in January 2023 shows vials and packaging for their medication, Leqembi. — Illustration: Alex Hogan/STAT; Photo: Eisai via AP

Seven months after US drug regulators fully approved Biogen’s treatment for Alzheimer’s disease, only about 2,000 patients are taking the medicine nationwide, the company said Tuesday.

Biogen’s chief executive, Christopher A. Viehbacher, said as the firm released fourth-quarter earnings that he had expected the slow uptake and sees considerable demand for the medication. He told reporters that 3,800 patients with early-stage Alzheimer’s have signed up on multiple registries to receive the drug, called Leqembi, as of last month.

Before patients can get the drug, which costs $26,500-a-year, they must undergo a brain scan or a spinal tap to confirm that they have build-up of deposits of a sticky toxic protein called beta-amyloid that is a hallmark of the disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： 30 years of 'Listening to Prozac'

focus

WSS

Diagnostic tests are hitting their mathematical limits

Readout Newsletter: Alnylam, Celldex, Roche, Zealand Pharma

Mayo Clinic plans $5B tech

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

FDA investigates CAR

In utero gene editing: an explainer

Wikipedia

fashion

focus

In Memoriam: Notable people who died in 2023

Neurocrine Biosciences, biotech based in San Diego, joins PhRMA

23andMe had bad news about my health. I wish a person had delivered it

Antivenom research: Lessons from HIV applied in search for universal antidote

Moonlake's readout produced a cash windfall. Risks remain

PBM reform efforts get punted in Congress

Sports medicine is finally prioritizing gender equality

Ed Silverman on new gene therapies, biosimilars, coffee, and more

At least 13 dead in Texas as scorching temps continue

As biotech industry slumps, bioscience job market is upside down

leisure time

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

How to pay for weight loss drugs and save Medicare

Despite FDA concern, risk that CAR

ReNAgade cuts staff seven months after raising $300 million

FDA investigates CAR

focus

leisure time

leisure time

hotspot